p. 2689−2698
2476-762X
Vol.14/No.5
p. 2699−2701
2476-762X
Vol.14/No.5
p. 2703−2706
2476-762X
Vol.14/No.5
p. 2707−2710
2476-762X
Vol.14/No.5
p. 2711−2715
2476-762X
Vol.14/No.5
p. 2717−2722
2476-762X
Vol.14/No.5
p. 2723−2729
2476-762X
Vol.14/No.5
p. 2731−2737
2476-762X
Vol.14/No.5
p. 2739−2742
2476-762X
Vol.14/No.5
p. 2743−2746
2476-762X
Vol.14/No.5
p. 2747−2751
2476-762X
Vol.14/No.5
p. 2753−2758
2476-762X
Vol.14/No.5
p. 2759−2763
2476-762X
Vol.14/No.5
p. 2765−2769
2476-762X
Vol.14/No.5
p. 2771−2776
2476-762X
Vol.14/No.5
0.7(p<0.01). Statistically non significant relationships defined only between the responses on amount of beer thecases drank at the ages up to 25 years and 26-35 years as well as time of use of estrogen and estrogens-progestinduring menopause by the cases. Moderate and substantial SCC and ICC were determined for different fooditems. Only the response of the cases on veal consumption did not correlate significantly. Conclusions. Thequestionnaire on breast cancer risk factors is valid and reliable for most of the questions included.]]>
p. 2777−2782
2476-762X
Vol.14/No.5
p. 2783−2787
2476-762X
Vol.14/No.5
p. 2789−2800
2476-762X
Vol.14/No.5
p. 2801−2803
2476-762X
Vol.14/No.5
p. 2805−2809
2476-762X
Vol.14/No.5
p. 2811−2818
2476-762X
Vol.14/No.5
p. 2819−2822
2476-762X
Vol.14/No.5
p. 2823−2828
2476-762X
Vol.14/No.5
p. 2829−2834
2476-762X
Vol.14/No.5
4 ng/ml) was found in 58 (3.8%). Abnormal DRE was found in 26 (1.72%). DRE and PSA were bothabnormal in 26 (1.72%) individuals. On the basis of raised PSA or abnormal DRE 58 (3.84%) individuals weresubjected to digitally guided trucut biopsy. Biopsy report revealed benign prostatic hyperplasia in 47 (3.11%)and adenocarcinoma prostate in 11 (0.73%). The specificity of DRE was 66.0%with a sensitivity of 90.9% anda positive predictive value of 38.5%. The sensitivity of PSA more than 4ng/ml in detecting carcinoma prostatewas 100% and the positive predictive value for serum PSA was 19.0% Conclusions: The overall cancer detectionrate in this study was 0.73% and those detected were locally advanced. Larger community-based studies arehighly warranted specially among high-risk groups.]]>
p. 2835−2838
2476-762X
Vol.14/No.5
SGC-7901 > MKN-28). Overexpression of miR-106b shortened the G0/G1 phase and accelerated cell cycleprogression, while reducing p21 and E2F5, without any significant effects on the capacity for migration andinvasion of gastric cancer cells. Conclusions: miR-106b may promote cell cycling of gastric cancer cells throughregulation of p21 and E2F5 target gene expression.]]>
p. 2839−2843
2476-762X
Vol.14/No.5
p. 2845−2850
2476-762X
Vol.14/No.5
p. 2851−2857
2476-762X
Vol.14/No.5
p. 2859−2863
2476-762X
Vol.14/No.5
p. 2865−2869
2476-762X
Vol.14/No.5
p. 2871−2877
2476-762X
Vol.14/No.5
0.05). EGFR mutations weredetected in tumor tissues from 27 of 49 NSCLC patients of Han ethnic group , with a positive rate of 55.1%;19 of them had exon 19 deletions, seven (7) had L858R point mutations in exon 21 of EGFR and one (1) hadmutations in both exon 18 G719X and exon 20 T790M of EGFR. Statistically significant differences were notedin EGFR genetic mutations between genders and between adenocarcinoma and non-adenocarcinoma (P<0.05),but not with age group, smoking status, or stage (P > 0.05). Conclusion: Statistically significant differences werenoted in the positive rates of EGFR genetic mutations in NSCLC patients between Uygur and Han ethnic groups,with lower positive rates for the Uygur cases.]]>
p. 2879−2883
2476-762X
Vol.14/No.5
p. 2885−2889
2476-762X
Vol.14/No.5
p. 2891−2896
2476-762X
Vol.14/No.5
p. 2897−2901
2476-762X
Vol.14/No.5
p. 2903−2908
2476-762X
Vol.14/No.5
0.05), whereas problems such as vomiting and fatigue did exerteffects (p<0.01). Conclusions: Patients with advanced stage lung cancer suffer from sleep problems and cancerrelated symptoms also affect their sleep quality negatively. Nurses should plan interventions that can controlsymptoms such as pain, vomiting and fatigue, which affect the sleep of patients.]]>
p. 2909−2913
2476-762X
Vol.14/No.5
p. 2915−2918
2476-762X
Vol.14/No.5
p. 2919−2923
2476-762X
Vol.14/No.5
p. 2925−2929
2476-762X
Vol.14/No.5
p. 2931−2936
2476-762X
Vol.14/No.5
p. 2937−2943
2476-762X
Vol.14/No.5
p. 2945−2948
2476-762X
Vol.14/No.5
p. 2949−2954
2476-762X
Vol.14/No.5
p. 2955−2958
2476-762X
Vol.14/No.5
p. 2959−2962
2476-762X
Vol.14/No.5
p. 2963−2966
2476-762X
Vol.14/No.5
p. 2967−2971
2476-762X
Vol.14/No.5
p. 2973−2978
2476-762X
Vol.14/No.5
p. 2979−2982
2476-762X
Vol.14/No.5
p. 2983−2986
2476-762X
Vol.14/No.5
RRM1>TUBB3>TYMS>BRCA1 in turn. By pairwise comparisons, other differences showed statisticalsignificance (p<0.05 or p<0.01) except for TYMS and TUBB3 (p>0.05); the low expression rates from high to lowwere ERCC1>TYMS>TUBB3>TUBB3>RRM1>BRCA1 in turn. The expression quantities of BRCA1, RRM1 andTYMS in males, smokers and patients without adenocarcinoma were all significantly higher than that in females,non-smokers and patients with adenocarcinoma, and significant differences were present (p<0.05 or p<0.01).In terms of pathological staging, the expression quantities of BRCA1, RRM1 and TYMS in phases Ⅱa~Ⅱb andⅢa~Ⅲb had a tendency to be greater than in phases Ⅰ and Ⅳ. Conclusions: Resistance to chemotherapy andsensitivity to targeted therapy differ among patients with NSCLC. Differences in gene expression in differentindividuals were also revealed. Only according to personalized detection results can individualized therapeuticregimens be worked out, which is a new direction for oncotherapy.]]>
p. 2987−2990
2476-762X
Vol.14/No.5
p. 2991−2999
2476-762X
Vol.14/No.5
p. 3001−3003
2476-762X
Vol.14/No.5
p. 3005−3010
2476-762X
Vol.14/No.5
p. 3011−3015
2476-762X
Vol.14/No.5
p. 3017−3021
2476-762X
Vol.14/No.5
p. 3023−3028
2476-762X
Vol.14/No.5
p. 3029−3035
2476-762X
Vol.14/No.5
p. 3037−3040
2476-762X
Vol.14/No.5
p. 3041−3044
2476-762X
Vol.14/No.5
p. 3045−3050
2476-762X
Vol.14/No.5
p. 3051−3056
2476-762X
Vol.14/No.5
p. 3057−3062
2476-762X
Vol.14/No.5
p. 3063−3066
2476-762X
Vol.14/No.5
p. 3067−3074
2476-762X
Vol.14/No.5
0.05). Conclusions. rs339331 in the RFX6 gene may be associated with prostate cancer as a susceptibility locusin northern Chinese men.]]>
p. 3075−3078
2476-762X
Vol.14/No.5
p. 3079−3083
2476-762X
Vol.14/No.5
p. 3085−3091
2476-762X
Vol.14/No.5
p. 3093−3099
2476-762X
Vol.14/No.5
p. 3101−3103
2476-762X
Vol.14/No.5
p. 3105−3108
2476-762X
Vol.14/No.5
p. 3109−3116
2476-762X
Vol.14/No.5
p. 3117−3121
2476-762X
Vol.14/No.5
p. 3123−3129
2476-762X
Vol.14/No.5
p. 3131−3137
2476-762X
Vol.14/No.5
p. 3139−3142
2476-762X
Vol.14/No.5
p. 3143−3149
2476-762X
Vol.14/No.5
p. 3151−3154
2476-762X
Vol.14/No.5
A Polymorphism and Lung Cancer Risk]]>
A polymorphism and riskof lung cancer, but the results have been inconsistent. Therefore, we performed a meta-analysis to obtain a moreprecise estimate. We searched the PubMed database up to March 1, 2013 for relevant cohort and case-controlstudies. Supplementary search was conducted manually by searching the references of the included studies andrelevant meta-analyses. A meta-analysis was performed using RevMan 5.2 software for calculation of pooledodds ratios (ORs) and relevant 95% confidence intervals (CIs) after data extraction. Finally, seven case-controlstudies and one nested case-control study involving 1,675 lung cancer patients and 2,393 controls were included.The meta-analysis showed that there was no association of CYP1A2 -163 C>A polymorphism with risk of lungcancer overall [(OR=0.89, 95%CI= 0.74-1.07) for C vs. A; (OR=0.73, 95%CI= 0.50-1.07) for AA vs. CC ; (OR=0.82,95%CI= 0.62-1.09) for AC vs. CC; (OR=0.79, 95%CI= 0.58-1.07) for (AC+AA) vs. CC; and (OR=0.87, 95%CI=0.67-1.13) for AA vs. (CC+AC)]. Subgroup analysis indicated that there was an associationbetween CYP1A2-163C>A polymorphism and lung cancer risk for population-based controls, a trend risk for SCCL (squamouscell carcinoma of lung) and Caucasians. These results suggested that -163 C>A polymorphism is likely to beassociated with risk of lung cancer compared with population-based controls.]]>
p. 3155−3158
2476-762X
Vol.14/No.5
p. 3159−3161
2476-762X
Vol.14/No.5
p. 3163−3168
2476-762X
Vol.14/No.5
p. 3169−3173
2476-762X
Vol.14/No.5
p. 3175−3176
2476-762X
Vol.14/No.5
p. 3177−3181
2476-762X
Vol.14/No.5
3cm vs ≤3cm; P=0.027), tumor location(lower vs upper/middle; P=0.009), vessel involvement (Yes vs No; P=0.001) and depth of invasion (T3-4a vsT1-2; P=0.012) were associated with 2.085-, 1.810-, 2.535- and 2.201- fold increases, respectively, for risk ofsubcarinal LN metastasis. Multivariate analyses showed that differentiation (poor vs well/moderate; P=0.001),subcarinal LN metastasis (yes vs no; P=0.033), depth of invasion (T3-4a vs T1-2; P=0.014) and N staging (N1-3vs N0; P=0.001) were independent prognostic factors. In addition, patients with subcarinal LN metastasis had asignificantly lower 5-year cumulative survival rate than those without (26.7% vs 60.9%; P<0.001). Conclusions:Subcarinal LN metastasis is a predictive factor for long-term survival in patients with ESCC.]]>
p. 3183−3186
2476-762X
Vol.14/No.5
p. 3187−3190
2476-762X
Vol.14/No.5
p. 3191−3196
2476-762X
Vol.14/No.5
p. 3197−3203
2476-762X
Vol.14/No.5
p. 3205−3211
2476-762X
Vol.14/No.5
T Gene Polymorphism in Differentiated Thyroid Cancers]]>
0.046). Conclusions:Presented results suggest that the MDR1 3435TT genotype might influence risk of development of DTC andthat the CC genotype might be linked to a poor prognosis. Large-scale studies are now needed to validate thisassociation.]]>
p. 3213−3217
2476-762X
Vol.14/No.5
p. 3219−3221
2476-762X
Vol.14/No.5
5cm) tumors to evaluate the association of IHC surrogate molecular subtypewith the clinical response to presurgical chemotherapy, evaluated by the WHO criteria, 3 weeks after the thirdcycle of 5 flourouracil, adriamycin, cyclophosphamide (FAC regimen). The subtypes of luminal, basal-like andHER2 enriched were found to account for 36.0 % (27/75), 34.7 % (26/75) and 29.3% (22/75) of patients respectively.Ten were luminal A and 14 luminal B (8 HER2 negative and 6HER2 positive). The triple negative breast cancer(TNBC) was most sensitive to chemotherapy with 19% achieving clinical-complete-response (cCR) followed byHER2 enriched (2/22 (9%) cCR), luminal B (1/6 (7%) cCR) and luminal A (0/10 (0%) cCR). Heterogeneity wasobserved within each subgroup, being most marked in the TNBC although the most responding tumors, 8%developing clinical-progressive-disease. The study supports association of molecular subtypes with response tochemotherapy in patients with advanced breast cancer and the existence of further heterogeneity within subtypes.]]>
p. 3223−3228
2476-762X
Vol.14/No.5
p. 3229−3235
2476-762X
Vol.14/No.5
p. 3237−3241
2476-762X
Vol.14/No.5
p. 3243−3254
2476-762X
Vol.14/No.5
5% (HR 2.05; p=0.034)were independent adverse prognostic factors for OS in NSCLC patients treated with erlotinib. Conclusions: Thisstudy suggests that NSCLC patients should be enrolled in erlotinib treatment after a first round of unsuccessfulchemotherapy to improve treatment success, during which they should be monitored for intra-abdominalmetastasis and weight loss.]]>
p. 3255−3261
2476-762X
Vol.14/No.5
p. 3263−3267
2476-762X
Vol.14/No.5
p. 3269−3274
2476-762X
Vol.14/No.5
p. 3275−3279
2476-762X
Vol.14/No.5
p. 3281−3288
2476-762X
Vol.14/No.5
p. 3289−3292
2476-762X
Vol.14/No.5
p. 3293−3298
2476-762X
Vol.14/No.5
p. 3299−3304
2476-762X
Vol.14/No.5
p. 3305−3308
2476-762X
Vol.14/No.5
G (missense mutation) is associated with increased risk of ~13fold (OR=12.8, 95%CI=1.71-96.71) for breast cancer. Significant associations were observed for each of thesevariations with both late menopause (p<0.01) and early menarche (p<0.005) cases when compared to controls.Our findings suggest that the polymorphic gene SYK may contribute to the development of breast cancer inat least the Pakistani population. This study provides an insight view of SYK which may provide a significantfinding for the pharmaceutical and biotechnology industry.]]>
p. 3309−3314
2476-762X
Vol.14/No.5
p. 3315−3318
2476-762X
Vol.14/No.5
p. 3319−3322
2476-762X
Vol.14/No.5
p. 3323−3329
2476-762X
Vol.14/No.5
p. 3331−3335
2476-762X
Vol.14/No.5
12 months) are needed whereoutcomes are detailed.]]>
p. 3337−3343
2476-762X
Vol.14/No.5
p. 3345−3349
2476-762X
Vol.14/No.5
p. 3351−3355
2476-762X
Vol.14/No.5
p. 3357−3362
2476-762X
Vol.14/No.5
p. 3363−3368
2476-762X
Vol.14/No.5
p. 3369−3373
2476-762X
Vol.14/No.5
p. 3375−3376
2476-762X
Vol.14/No.5